![]() | ![]() |
Formats:
|
||||||||||||||||||||||||||||||||||
Roles of transient receptor potential channels in pain a Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA b The Scripps Research Institute, Department of Cell Biology, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA c Department of Oral and Maxillofacial Surgery, University of Texas Health Sciences Center San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA d Departments of Medicine and Neurobiology, University of Pittsburgh, E1453 BSTWR 3500 Terrace Street, Pittsburgh, PA 15261, USA e Neurobiology Section, Department of Biological Sciences, University of Southern California, Los Angeles, California 90089, 3641 Watt Way, HNB 228, University of Southern California, Los Angeles, CA 90089, USA f Washington University Pain Center, Department of Anesthesiology, Washington University School of Medicine, 660 S. Euclid Avenue, Campus Box 8054 St. Louis, MO 63110, USA *Corresponding author. Fax: +1 414 456 6517. E-mail addresses: cstucky/at/mcw.edu (C.L. Stucky), Email: adubin/at/scripps.edu (A.E. Dubin), Email: jeske/at/uthscsa.edu (N.A. Jeske), Email: sam64/at/pitt.edu (S.A. Malin), Email: mckemy/at/usc.edu (D.D. McKemy), Email: story/at/wustl.edu (G.M. Story) 1Fax: +1 858 784 7084. 2Fax: +1 210 567 2995. 3Fax: +1 412 648 9731. 4Fax: +1 314 362 8334. The publisher's final edited version of this article is available at Brain Res Rev.Abstract Pain perception begins with the activation of primary sensory nociceptors. Over the past decade, flourishing research has revealed that members of the Transient Receptor Potential (TRP) ion channel family are fundamental molecules that detect noxious stimuli and transduce a diverse range of physical and chemical energy into action potentials in somatosensory nociceptors. Here we highlight the roles of TRP vanilloid 1 (TRPV1), TRP melastatin 8 (TRPM8) and TRP ankyrin 1 (TRPA1) in the activation of nociceptors by heat and cold environmental stimuli, mechanical force, and by chemicals including exogenous plant and environmental compounds as well as endogenous inflammatory molecules. The contribution of these channels to pain and somatosensation is discussed at levels ranging from whole animal behavior to molecular modulation by intracellular signaling proteins. An emerging theme is that TRP channels are not simple ion channel transducers of one or two stimuli, but instead serve multidimensional roles in signaling sensory stimuli that are exceptionally diverse in modality and in their environmental milieu. Keywords: TRPA1, TRPV1, TRPM8, Cold, Mechanotransduction, Nociceptor, Sensory neuron, Cutaneous, Inflammation, Prostaglandin, NGF, Artemin, Bradykinin, Kinase, Scaffold protein 1. Introduction The Transient Receptor Potential (TRP) superfamily of ion channels comprises proteins with six transmembrane domains and cytoplasmic N- and C-termini. TRP proteins assemble as homo- or heterotetramers to form cation-permeable ion channels (Voets et al., 2005). Currently, 28 TRP channels have been discovered in mammals and based on their sequence homology, are classified into six subfamilies: TRPC, TRPV, TRPM, TRPA, TRPP and TRPML (Montell, 2005). This review highlights recent discoveries describing the roles of TRPV1, TRPM8 and TRPA1 in transduction and sensitization in primary afferent somatosensory neurons. The first TRP channel discovered in mammalian sensory neurons was Transient Receptor Potential Vanilloid 1 (TRPV1). TRPV1 is the obligate receptor for capsaicin, the spicy ingredient in hot chili peppers, and also a key receptor for noxious physical heat (>42 °C; Caterina et al., 1997). TRPV1 is found on many small-medium-diameter nociceptive sensory neurons which are likely to have C fiber axons (Tominaga et al., 1998). The identification of TRPV1 was the major catalyst that launched the fields of somatosensory and pain transduction research to the molecular level, and discovery of additional TRP family members rapidly followed. TRP melastatin 8 (TRPM8) was subsequently discovered in 2002 and found to be strongly activated by the cool-mimetic chemical menthol and by physical cooling (McKemy et al., 2002; Peier et al., 2002). TRPM8 is located in small- and medium-diameter sensory neurons within the trigeminal and dorsal root ganglia. Recently, three independent studies of TRPM8-null mice have firmly established that TRPM8 is a major cold and cooling transduction channel in mammalian sensory neurons (McKemy et al., 2002; Peier et al., 2002; Bautista et al., 2007; Dhaka et al., 2007; Colburn et al., 2007). Transient Receptor Potential Ankyrin 1 (TRPA1) is the only member of the ankyrin subfamily found in mammals. Originally called ANKTM1, TRPA1 was identified by a homology search for ankyrin domains and six transmembrane domains and is 20% homologous at the amino acid level to TRPV1 (Jaquemar et al., 1999; Story et al., 2003). Its structure is distinct from other TRP channels as it is the only member with an extended (14–17) ankryin repeat domain in the N-terminus (Clapham, 2003). TRPA1 channels are expressed in a subpopulation of unmyelinated nociceptors that also express the capsaicin receptor TRPV1, suggesting an important role in nociception. Consistent with this posit, TRPA1 is activated by a diverse assortment of pungent or irritating reactive chemical compounds including those found in mustard oil (allyl isothiocyanate), cinnamon oil (cinnamaldehyde), gas exhaust (acrolein), raw garlic and onions (allicin) and formalin (formaldehyde); all of these elicit a painful burning or prickling sensation (Story et al., 2003; Bandell et al., 2004; Jordt et al., 2004; Macpherson et al., 2005; Bautista et al., 2006; McNamara et al., 2007). Moreover, TRPA1 has been put forth as a putative transducer of natural physical stimuli including both cold and mechanical force (Story et al., 2003, Corey et al., 2004). Thus, a common theme has emerged whereby TRPA1 is found in nociceptors and the modality(s) of nociception to which it mechanistically contributes appear to be quite diverse. Like TRPV1 (Caterina et al., 2000), TRPA1 may be a molecular “switchboard” integrator for a range of diverse noxious stimuli. In this article, we focus on these three principal sensory transduction channels and their roles in processes that span from whole animal pain behavior down to their molecular modulation by signaling proteins. On an anatomical level, we review recent work illuminating the central and peripheral projections of TRPM8-expressing neurons. At the primary afferent function level, we review the evidence supporting a role for TRPA1 in both cold transduction and mechanotransduction incutaneous sensory neurons. On a cellular level, we discuss recent discoveries of both endogenous inflammatory mediators and exogenous irritating chemicals that activate TRPA1. Finally, on a membrane signaling level, we detail the capacity of growth factors to modulate TRPA1 and TRPV1 channel activity, and discuss the roles of scaffolding proteins that assist kinases and phosphatases in diversely modulating these ion channels. 2. Diversity in the neural circuitry of cold sensing revealed by genetic axonal labeling of TRPM8 neurons Cold temperatures activate a small cohort of sensory neurons, yet generate a variety of distinct sensations that range from pleasantly cool to painfully aching, prickling, and burning. Cold responses are mediated through both C and Aδ fibers, each of which likely provides one or more of these distinct cold sensations. Remarkably the majority of cold responses in vivo are dependent upon the cold and menthol receptor TRPM8. In vitro, TRPM8 currents are evoked as temperatures drop below ~26 °C, and over a range of both innocuous cool and noxious cold temperatures (McKemy et al., 2002; Peier et al., 2002). In vivo, TRPM8-null mice are deficient in detecting innocuous cool temperatures and exhibit a partially defective phenotype in responding to noxious cold (Bautista et al., 2007; Colburn et al., 2007; Dhaka et al., 2007). Cold-evoked responses in both Aδ and C fibers are greatly reduced, if not absent in these animals (see section 5). Moreover, activation of TRPM8 is required for the analgesia provided by cooling and cooling compounds (Proudfoot et al., 2006; Dhaka et al., 2007) and, paradoxically, is essential in injury-evoked hypersensitivity to cold (Colburn et al., 2007; Dhaka et al., 2007). Thus, TRPM8 plays a key role in the perception of cold temperatures and raises the question: how can a single receptor contribute to multiple, and in some cases antagonistic (pain versus analgesia), aspects of sensory signaling? To begin to address this question, transgenic mice expressing a genetically encoded axonal tracer (Green Fluorescent Protein; GFP) that fluorescently labels TRPM8 neurons and axons in vivo were generated, and their neurochemical phenotype and central and peripheral projections examined (Takashima et al., 2007). 2.1. TRPM8 is expressed by somata of nociceptors and non-nociceptors Consistent with the broad range of functional roles of the channel, TRPM8 neurons express markers of nociceptors as well as non-nociceptors, and have axonal properties indicative of both Aδ and C fibers. TRPM8 expression co-labels with the neurofilaments NF200 (Fig. 1a
2.2. TRPM8 is expressed by nociceptors and thermoreceptors innervating the tooth These data show that TRPM8 neurons are heterogeneous neurochemically and that TRPM8 is expressed in both C and Aδ fibers which are presumptive nociceptors. These findings suggest that TRPM8 is involved in both nociceptive and non-nociceptive sensory signaling. However, these results are based on somal expression and may not be indicative of the properties of the terminals of these neurons in the periphery. Psychophysical and functional data have shown cool fibers and noxious cold fibers to have distinct receptive zones in many peripheral tissues, such as skin and teeth (Darian-Smith et al., 1973; Jyvasjarvi and Kniffki, 1987; Davis, 1998). Thus, various peripheral projections of TRPM8 fibers were examined to determine if they innervate tissues in a manner that suggests both innocuous and noxious cold signaling, with the hypothesis that expression would be found in morphologically distinct subtypes of neurons or neural circuits. The best studied fibers for localization of receptive zones of distinct cold fiber-types are found in the tooth dentin and pulp (Byers and Narhi, 2002). In human and animal studies, the first and second pains evoked by cold stimulation of the tooth are attributed to cold-sensitive Aδ and C fibers, respectively (Jyvasjarvi and Kniffki, 1987). More critically, cold-sensitive Aδ and C fibers have distinct receptive fields, with superficial endings of Aδ fibers located to the dentin and C fibers deeper in the pulp (Fig. 2b
2.3. TRPM8 is expressed by diverse cutaneous afferents that mediate cooling and noxious cold Next, it was determined if this diversity in receptive zones innervated by TRPM8 fibers is restricted to the tooth, or also occurs in other peripheral tissues such as skin. For cold-sensitive nerves, psychophysical and functional data suggest that innocuous cool fibers are located superficial to noxious cold fibers in the skin (Davis, 1998; Harrison and Davis, 1999). From these data, along with findings that TRPM8 neurons are both peptidergic and non-peptidergic, it was determined if the peripheral terminals of GFP-positive axons are restricted to a single epidermal domain, or terminate throughout the epidermis in a manner indicative of disparate functional fiber-types. The localization of TRPM8 axon terminals in glabrous skin was examined, where the epidermis is separated into 4 distinct layers demarcated by keratinocyte organization. TRPM8-expressing axon terminals were found near the epidermal/dermal boundary as well as in the stratum granulosum (SG), the most superficial live cell layer of the epidermis (Figs. 2c–e 2.4. TRPM8 is a molecular fulcrum that conveys both innocuous cooling and painful cold In conclusion, the preponderance of evidence coming from human, animal, and cellular studies suggests that the neural substrates for cold signaling are diverse. However, recent analyses of TRPM8-null mice suggest that this lone ion channel is the prime molecular detector of cold, and initiates the majority of these responses (Bautista et al., 2007; Colburn et al., 2007; Dhaka et al., 2007). Here evidence shows that TRPM8 is expressed in several neuronal subtypes and that, while it endows these cells with cold sensitivity, other mechanisms likely help determine the resulting perceptual outcome of their activation. These results further demonstrate that the peripheral neural circuitry of cold sensing is cellularly and anatomically complex, yet suggest that cold fibers, due to the diverse neuronal context of TRPM8 expression, use a single molecular sensor to convey a wide range of cold sensations. Whether different TRPM8-expressing afferents are endowed with distinct functional properties, or are in segregated neural circuits, needs to be addressed by functional recordings in intact preparations and circuit tracings in vivo. Such analyses of these and other afferent subtypes will shed light on the neural correlates of somatosensory signaling and establish the basis for genetic manipulation of neural function, the mapping of somatosensory neural networks, and the elucidation of intricacies of sensory coding in the somatosensory system. 3. Role of TRPA1 in acute cold and mechanical transduction in cutaneous nociceptors 3.1. TRPM8 is a major receptor for cooling and noxious cold As detailed earlier in section 2.0, the majority of cold responses in mammals are mediated by the cold and menthol receptor TRPM8. Three independent laboratories generated TRPM8-null mice and through an array of phenotypic analyses from molecular to behavioral levels, demonstrate collectively that TRPM8 is a key receptor for both cooling and noxious cold (Bautista et al., 2007; Colburn et al., 2007; Dhaka et al., 2007). In one of these reports (Bautista et al., 2007), our laboratory utilized an ex vivo skin-saphenous nerve preparation to characterize the physiological responses of cutaneous C and Aδ fibers to cold stimuli (32 to 2 °C in 20 s) applied to the receptive terminals in situ (Fig. 3a
3.2. Is TRPA1 a noxious acute cold receptor? Whether or not TRPA1 is a noxious cold sensor, via either direct or indirect mechanism, is uncertain. On one hand, some research groups have shown that when TRPA1 is expressed in heterologous systems, human embryonic kidney (HEK) cells or Chinese hamster ovary (CHO) cells, it is activated by cold temperatures, ~17 °C and below that are in the noxious range (Story et al., 2003, Bandell et al., 2004; Sawada et al., 2007). Alternatively, other laboratories have found that exogenously-expressed TRPA1 is not activated by noxious cold (Bautista et al., 2006, Jordt et al., 2004, Nagata et al., 2005). A plausible answer to this discrepancy has come from two recent studies which showed that TRPA1 can be directly activated by intracellular Ca2+ via an EF-hand domain in its N-terminal domain (Doerner et al., 2007; Zurborg et al., 2007), leading one group to conclude that the cold-sensitivity of TRPA1 occurs indirectly through cold-induced release of intracellular Ca2+ (Zurborg et al., 2007). Definitive evidence of the role of TRPA1 in cold somatosensation could be provided by analysis of mice lacking the TRPA1 gene. Two groups generated TRPA1-deficient mice, but came to different conclusions based on behavioral tests. One laboratory found significant deficits in assays for acute noxious cold sensation, including withdrawal responses from ice-cold plate and acetone-evoked cooling (Kwan et al., 2006), whereas the other group found no significant cooling deficits in TRPA1-null mice compared to wild type littermates in cellular or behavioral assays (Bautista et al., 2006). Some explanations for the discrepancy in behavioral results may be differences in the test methods used or differences in gender of animals used. Beyond its disputed role in acute cold transduction, TRPA1 has also been proposed to contribute to cold hyperalgesia or allodynia after injury. In animal models, TRPA1 mRNA is reported to be upregulated after both tissue inflammation and peripheral nerve injury, and antisense knock down of TRPA1 alleviates cold hyperalgesia (Obata et al., 2005; Katsura et al., 2006). 3.3. Is TRPA1 involved in sensory mechanotransduction? Adding further diversity to its potential physiological roles, TRPA1 has also been proposed to be involved in mechanotransduction. Evidence has been put forth from a range of evolutionary levels of species from fly to mammals. Drosophila larvae deficient in a TRPA homologue called painless have decreased behavioral responses to intense mechanical stimuli (Tracey et al., 2003). C. elegans with mutations in the Trpa1 gene fail to show head withdrawal or to cease feeding following nose touch (Kindt et al., 2007). Mice with a deletion of the pore domain of TRPA1 exhibit decreased behavioral responses to intense mechanical force in the noxious range (Kwan et al., 2006), although behavioral deficits to mechanical stimuli were not observed in a similar TRPA1 mutant mouse (Bautista et al., 2006). A small molecule inhibitor of TRPA1 reverses mechanical hyperalgesia induced by inflammation in mice (Petrus et al., 2007). No cellular studies have provided clear evidence that TRPA1 is directly gated by mechanical force, although a recent study shows that heterologously-expressed TRPA1 is activated by hypertonic saline, suggesting that TRPA1 is sensitive to osmotic stimuli (Zhang et al., 2008). However, it should be noted that the nature of osmotic stimuli and how it activates channels in a cell membrane may differ substantially from that of punctuate mechanical force applied to a localized region of the neuronal membrane. 3.4. Factors to consider when investigating sensory transduction molecules To understand the physiological role of TRPA1 in acute cold or mechanical transduction, or in sensitization to cold or mechanical stimuli after tissue injury, it is important to carefully consider the models and techniques used because a wide range of factors could influence the results and conclusions. Some of the important variables to consider are as follows: 1) the fact that the cellular milieu surrounding the TRPA1 channel differs substantially when it is expressed in heterologous cells versus native dorsal or trigeminal ganglia, 2) the physiological relevance of the region of the sensory neuron should be considered because sensory terminals in vivo or in situ may contain different levels of ion channel expression than the soma membrane. 3) the tissue setting because TRPA1 expressed by neurons in injured or inflamed tissue may have different physiological properties than that expressed in naïve, uninjured skin; 4) the manipulation of tissue used in experiments since isolated somata from dorsal or trigeminal ganglia may be “injured” via the axotomy induced during ganglia removal or dissociation, and neurons may be altered by the effects of the culture milieu and growth factors; 5) the fact that different components that are integrated into the response of a single cell, neural pathway or whole animal behavior. The ex vivo skin nerve preparation provides a way to measure the response properties of single identified cutaneous fibers to natural cold and mechanical stimuli. Advantages of this approach are that terminals of sensory neurons remain intact in their natural environment in the skin and that quantitative physiological stimuli can be applied to the receptive terminal. Our goals are to determine the role of TRPA1 in the response properties of C and Aδ fibers in non-injured skin to acute cold and mechanical stimuli by using TRPA1-deficient mice. A further goal is to determine the role of TRPA1 in the sensitization of nociceptors to cold or mechanical force following persistent nerve or tissue injury. 4. TRPA1 activation by endogenous mediator prostaglandin D2 metabolite, 15d-PGJ2 The TRPA1 channel is best characterized as a “chemoTRP” activated by a diverse myriad of noxious environmental chemicals (see section 1). Besides exogenous compounds, TRPA1 is also activated and/or modulated by chemicals originating from within the body, including arachadonic acid, bradykinin and products of oxidative stress (Andersson et al., 2008; Bandell et al., 2004). Our search for endogenous chemical activators utilized a bioactive lipid library screen and identified a cyclopentane prostaglandin D2 metabolite, 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), as a TRPA1 agonist (Cruz-Orengo et al., 2008). Unlike other TRPA1 agonists, 15d-PGJ2 has not been previously shown to evoke nociceptive responses; rather it mediates anti-inflammatory processes. However, we find that 15d-PGJ2 evokes acute nociceptive behaviors in rodents when injected into the skin and does so via a TRPA1-dependent mechanism. 4.1. Synthesis of 15d-PGJ2 and roles in vivo The prostaglandins (PGs) are a class of biomolecules derived from arachidonic acid that are involved in a variety of signaling processes. The synthesis of all prostaglandins begins with the enzymatic cyclooxygenation of arachidonic acid to produce prostaglandin H2 (PGH2). PGH2 is then converted into other PGs by the activity of several prostaglandin synthases, which are differentially-expressed depending on cell type and on response to external stimuli. The arachadonic acid cascade generally promotes an inflammatory response. For example, PGE2 and PGI2 are produced during inflammation, resulting in vasodilation, edema and rubor. They also contribute to the direct sensitization of nociceptive neurons of the dorsal root ganglia (DRG), resulting in hyperalgesia and allodynia (Nakae et al., 2005; Stucky et al., 1996). For example, one mechanism whereby PGE2 sensitizes nociceptive neurons to thermal stimuli occurs via the vanilloid Transient Receptor Potential channel, TRPV1. Downstream of binding to its G protein-coupled receptor (GPCR), PGE2 sensitizes TRPV1 via specific PKA-dependent phosphorylation (Hu et al., 2002). Prostaglandin D2 (PGD2) is the most abundant prostanoid in mammalian brain tissue. Although PGD2 has been implicated primarily in the regulation of sleep, evidence also indicates that it contributes to the processing of pain signals in the central nervous system (Urade and Hayaishi, 2000). Like other prostaglandins, PGD2 acts via specific GPCRs, designated DP1 and DP2 (D-type prostanoid receptors), which are expressed in the membranes of target cells. Two subsequent non-enzymatic dehydrations of PGD2 result in the production of Δ12-Prostaglandin-J2 (Δ12-PG J2) and 15d-PGJ2. Recently, 15d-PGJ2 has been characterized as a potent anti-inflammatory agent rather than a molecule that induces acute or long-term inflammatory pain. In fact, the resolution of the inflammatory state appears to correlate with increasing levels of 15d-PGJ2 within tissue fluids (Gilroy et al., 1999). Like other cyclopentane prostaglandins, 15d-PGJ2 does not function via a specific membrane-bound GPCR. Rather, the anti-inflammatory effects of 15d-PGJ2 are mediated by activation of the transcription factor peroxisome proliferator-activated receptor gamma (PPARγ; Forman et al., 1996, Soares et al., 2005; Straus et al., 2000). The 15d-PGJ2 is suspected to release cytoplasmic PPARγ from repressor proteins, enabling it to translocate to the nucleus and initiate the transcription of genes containing the PPAR-response element. For example, 15dPGJ2 represses the transcription of a number of pro-inflammatory factors including inducible nitric oxide synthase, cyclooxygenase-2 and tumor necrosis factor-α (Jiang et al. 1998; Ricote et al., 1998). 15d-PGJ2 also acts independent of PPARγ to alter the activity of inflammatory molecules. It is thought to directly alkylate nucleophilic cysteine residues of NF-κB, thereby inhibiting DNA binding by NF-κB (Kliewer et al., 1995). 4.2. 15d-PGJ2 directly activates TRPA1 expressed in heterologous cells Results of our studies reveal a previously uncharacterized role of 15d-PGJ2 in peripheral nociception. We show that 15d-PGJ2, like all other known TRPA1 ligands, induces pain. We further demonstrate a causal link between 15d-PGJ2-induced nociception and TRPA1 activation at the cellular and behavioral levels. Similar to allyl isothiocyanate (AITC) and cinnamaldehyde, 15d-PGJ2 is characterized by an electrophilic α,β-unsaturated carbonyl group that is capable of undergoing a Michael addition with nucleophilic groups on cysteine residues. Two groups have shown that TRPA1 is activated by the covalent binding of electrophiles to cysteines, providing a likely mechanism whereby 15d-PGJ2 activates this channel (Hinman et al., 2006; Macpherson et al., 2007a). The results of our initial compound library screen were borne out by follow-up electrophysiological recordings showing that 15d-PGJ2 directly activates TRPA1. In contrast to 15d-PGJ2, the J series PGD2 metabolites PGJ2 and 12d-PGJ2, which also contain reactive electrophilic carbons, failed to activate TRPA1 in our studies. A recent study by Taylor-Clark et al. (2008) which examined the activation of human TRPA1 using heterologous expression in HEK cells, found that 12d-PGJ2 was able to activate this channel. Discrepancies between this study and our study could be due to concentrations tested (5 times greater concentrations were utilized by Taylor-Clark and colleagues), expression systems used or to subtle species differences in channel structure. The in vivo behavioral studies described here extend those of Taylor-Clark and colleagues by demonstrating that 15d-PGJ2 activation of TRPA1 is physiologically relevant. During the preparation of this manuscript, Andersson and co-workers published an article on the activation of TRPA1 by mediators of oxidative stress (including 15d-PGJ2) which confirms our findings presented here (Andersson et al., 2008; Cruz-Orengo et al., 2008). 4.3. 15d-PGJ2 directly activates TRPA1 in native dorsal root ganglia neurons Consistent with a physiological role of 15d-PGJ2 in the activation of TRPA1, we identified a population of DRG neurons that are sensitive to 15d-PGJ2, AITC and capsaicin. TRPA1-expressing neurons occur as a subset of TRPV1-expressing neurons in the DRG; whereas TRPM8 is expressed in a population distinct from TRPA1 (Story et al., 2003). These results support our electrophysiological studies showing that 15d-PGJ2 does not activate TRPV1 or TRPM8. In further support of specific activation of TRPA1, a negligible number of 15d-PGJ2/AITC responsive neurons were detected in cultures derived from TRPA1 knockout mice compared to wildtype (~2% vs. 90% respectively). 4.4. 15d-PGJ2 causes acute behavioral nociception via TRPA1 Specific agonists of TRPA1 cause acute nociceptive behaviors in vivo when injected into hind paw skin (Bandell et al., 2004; Bautista et al., 2006). Therefore, we investigated the behavioral responses to intraplantar injection of 15d-PGJ2 in mice. Both C57BL/6J and TRPA1 wildtype mice responded robustly by licking of the injected paw as well as lifting of the paw from the surface of the testing apparatus (Figs. 4a, b
Previous studies have demonstrated a definitive role of TRPA1 in transmitting acute and inflammatory pain (Bandell et al., 2004; Bautista et al., 2006; Hinman et al., 2006; Macpherson et al., 2005; McNamara et al., 2007; Kwan et al., 2006). Here we show that 15d-PGJ2, a molecule with no previously-identified membrane receptor, specifically activates TRPA1, an ion channel expressed in the cell membrane of nociceptive neurons. Whereas previous studies have implicated roles for 15d-PGJ2 in anti-inflammatory pathways, we demonstrate a novel role for this molecule in acute pain. We demonstrate that similar to other TRPA1 agonists, 15d-PGJ2 induces robust, acute nociceptive behaviors in vivo. Our data also support that 15d-PGJ2-induced peripheral nociception in vivo occurs via TRPA1 signaling. Collectively, our findings elaborate a novel function of 15d-PGJ2 in peripheral nociception and identify TRPA1 as its principal receptor in pain-sensing DRG neurons. 4.5. Open questions Does 15d-PGJ2 have therapeutic potential? Is TRPA1 involved at all in the pathways whereby 15d-PGJ2 participates in the resolution of inflammation? What are the effects of 15d-PGJ2 on peripheral inflammatory pain? Two studies have examined the effects of peripheral 15d-PGJ2 administration on nociception in the context of inflammation using the carrageenan and formalin models and found it to be anti-nociceptive (Napimoga et al., 2008a, b). Further studies using TRPA1 knockout animals will resolve whether this channel is involved in these anti-nociceptive effects of 15d-PGJ2. A possible mechanism might involve 15d-PGJ2-induced direct desensitization of the TRPA1 channel in mechanically-sensitive sensory neurons. 5. Mechanisms of TRPA1 activation and modulation in inflammatory pain Defining the extent of the contribution of TRPA1 to the etiology of spontaneous pain and thermal and mechanical hyperalgesia in persistent inflammation is important for analgesic discovery. As mentioned earlier, TRPA1 signals the presence of a plethora of noxious stimuli in our environment and endogenous molecules released in inflamed tissues. TRPA1 is activated by a large set of chemically diverse compounds that have in common their reactivity with amino acid residues in the N terminal cytoplasmic domain (Macpherson et al., 2007a; Hinman et al., 2006). One widely used inflammatory pain model utilizes formalin, a small reactive aldehyde (formaldehyde; Fig. 5a
5.1. Formalin directly and selectively activates TRPA1 Because of its reactive properties, it was hypothesized that formaldehyde would activate TRPA1. Activation of TRPA1 by formaldehyde was initially tested in heterologous cells transfected with TRPA1 by using the high throughput fluorescent imaging plate reader (FLIPR) and electrophysiology (Figs. 5a, c
5.2. Behavioral responses to formalin depend on TRPA1 We next sought to determine whether formalin elicits inflammatory pain behaviors via a TRPA1-dependent mechanism by using a genetic approach employing TRPA1-null mice. The early phase (0–10 min) of the behavioral response to formalin is thought to be predominantly caused by peripherally-driven C-fiber activation, while the late phase (10–30 min) depends on a combination of peripheral tissue factors and functional changes in the dorsal horn of the spinal cord initiated by the C-fiber barrage during the first phase (Tjolsen et al., 1992). Both the early and late phases of formalin-induced nocifensive behaviors were significantly reduced in TRPA1−/− mice relative to their wild type littermates (Fig. 6b 5.3. TRPA1 contributes to inflammatory mechanical hyperalgesia To evaluate the role of TRPA1 activity in animal models of pain, we sought to find a selective pharmacological inhibitor of TRPA1. Using an agonist–antagonist formatted FLIPR assay to screen a library of ~44,000 chemicals, we identified AP18. Compound AP18 effectively blocked the response to cinnamaldehyde, had no inherent agonist activity (Figs. 7a–c
Next, AP18 was used to explore the relative contribution of TRPA1 to the hyperalgesia and allodynia associated with persistent inflammation. Cutaneous inflammation was induced via injection of the hind paw with Complete Freund’s Adjuvant (CFA) in both wild type and TRPA1 null mice. By 24 h later, both genotypes had developed marked mechanical hyperalgesia (Fig. 8
5.4. TRPA1 contributes to inflammatory cold hyperalgesia Direct activation of TRPA1 by noxious cold temperatures has been heatedly debated by a number of different investigators, and it is likely that second messengers such as intracellular calcium contribute to the activation of TRPA1 in response to cold stimuli (Zurborg et al., 2007). Using a pharmacological approach we sought to determine whether TRPA1 contributed to CFA induced cold hyperalgesia. Conflicting results have been reported on the role of TRPA1 in sensing noxious cold temperatures in TRPA1-deficient mice. One group observed a partial deficit in response to cold in two different behavioral assays (Kwan et al., 2006) while the other group found no cold deficits (Bautista et al., 2006). The differences observed may depend on the choice of gender used (the cold deficits were observed only in females; Kwan et al., 2006), the different methods used for assaying cold-evoked behavioral responses, or the difficulty of observing responses to noxious cold stimuli in mice, particularly of different genetic backgrounds. However, a robust cold-induced hyperalgesia has been reported in rats (Obata et al., 2005; Allchorne et al., 2005). Placing a rat on a 5 °C cold plate induces nocifensive behaviors such as licking/flicking the paw and non-coordinated paw lifting. TRPA1 antisense but not control oligodeoxynucleotides reverse the cold hyperalgesia after CFA-induced inflammation, indicating a role for TRPA1 in cold hyperalgesia (Obata et al., 2005). Thus, we investigated whether AP18 could reverse CFA-induced cold hyperalgesia in Sprague–Dawley rats. In comparison to basal nocifensive responses before CFA injection, CFA-induced inflammation elicited a hyperalgesic response to noxious cold as evident by a marked increase in the number of cold-evoked responses (Fig. 9
Thus, using genetic and pharmacological approaches, the composite of these data suggest that TRPA1 plays a major role in the inflammatory pain induced by formalin injection as well as in the mechanical and cold hyperalgesia that is associated with peripheral inflammation. The mechanism by which TRPA1 contributes to inflammatory pain is not known. Whether native mammalian TRPA1 can be directly gated by noxious mechanical forces and cold temperatures, and the extent that upstream messengers or accessory proteins participate in TRPA1-mediated pain behaviors are currently unanswered questions. 6. Growth factor modulation of TRP channels 6.1. Proposed role for TRPA1 in inflammatory pain Previous studies have demonstrated that TRPV1 is critical to a variety of chronic pain states: cutaneous inflammatory pain (Caterina et al., 2000), bone cancer pain (Ghilardi et al., 2005), incisional pain (Pogatzki-Zahn et al., 2005), bladder cystitis pain (Charrua et al., 2007), and colonic hypersensitivity (Jones et al., 2007). Interestingly, TRPA1−/− mice lack responsiveness to bradykinin, a major effector of TRPV1 potentiation and inflammatory pain, and recent studies using TRPA1-specific inhibitors also suggest a role for TRPA1 in inflammatory hyperalgesia (Kwan et al., 2006; McNamara et al., 2007; Petrus et al., 2007). However, little is known about the function and modulation of TRPA1 in chronic pain. 6.2. Growth factor modulation of TRPA1 and TRPV1 Modulation of TRPA1 by bradykinin-, growth factor- and TRPV1-gated pathways has important implications for possible roles for this channel in acute and chronic pain conditions. Growth factors such as NGF, GDNF, neurturin and artemin are dynamically regulated in peripheral tissues in response to injury. In particular, expression of NGF and artemin is dramatically elevated in inflamed tissue during the period of hyperalgesia (Malin et al., 2006; Fig. 10
We have also shown that injections of GDNF family members (artemin, neurturin and GDNF) or NGF into the hindpaw cause acute thermal hyperalgesia lasting >4 h (Fig. 12
6.3. TRPA1 and TRPV1 may functionally interact TRPV1 and TRPA1 are expressed inlargely overlapping subsets of nociceptors (Bautista et al., 2005; Kobayashi et al., 2005), and both channels are implicated in inflammatory thermal hyperalgesia. Surprisingly, TRPV1−/− mice show reduced response to mustard oil, a TRPA1 ligand (Caterina et al., 2000). Thisresult suggests that TRPA1 function is impaired in the absence of TRPV1. Furthermore, behavioral and electrophysiological responses to the pro-inflammatory peptide bradykinin, previously demonstrated to require TRPV1, are impaired in TRPA1−/− mice (Ferreira et al., 2004; Bautista et al., 2006; Kwan et al., 2006). These results suggest that TRPA1 may be critical to TRPV1 function. A recent report describes cross-desensitization of TRPA1 and TRPV1 in vitro, further supporting the hypothesis that TRPA1 and TRPV1 are functionally linked in sensory neurons in vivo (Akopian et al., 2007). The mechanism for this interaction is unknown, but may involve regulation of one channel by calcium entry through the other (Doerner et al., 2007; Zurborg et al., 2007), direct channel–channel interaction within the plasma membrane and/or co-assembly of TRPV1 and TRPA1 subunits into heteromultimeric channels. In addition, TRP channel activation results in activation of second messenger signaling cascades that may modify both TRPV1 and TRPA1. These findings suggest a previously-unsuspected mechanism for the regulation of noxious sensation, and beg the question of whether TRPA1, like TRPV1, is potentiated by endogenous inflammatory mediators. 6.4. Sensitization of TRPA1 and TRPV1 by second messengers In sensory neurons, repeated TRPA1 activation by 100 μM mustard oil results in profound desensitization of the TRPA1 channel (Fig. 13
Recently, bradykinin-induced sensitization of TRPA1 has been demonstrated in vivo and appears to involve both PLC and PKA pathways in sensory neurons (Wang et al., 2008). Furthermore, these effects are additive, suggesting that TRPA1 may integrate signals from multiple activators of PLC and PKA during sensory signaling (Wang et al., 2008). Because of the high structural and functional homology between TRPV1 and TRPA1, it seems likely that growth factors and inflammatory mediators potentiate TRPA1 function through inhibition/blockade of TRPA1 desensitization. In addition to modulatory action of bradykinin on TRPA1 channels through PLC and PKA, TRPA1 channels are also opened by bradykinin. This effect requires the bradykinin receptor, and is, therefore, likely to occur through second messenger pathways downstream of bradykinin receptors, as opposed to direct channel gating of TRPA1 by bradykinin (Bandell et al., 2004; Bautista et al., 2006; Kwan et al., 2006). These data suggest that other PLC and PKA activators may gate or modulate TRPA1 channels in sensory neurons (Fig. 14
6.5. TRPA1 may integrate multiple stimuli in sensory neurons Interestingly, a soluble intracellular polyphosphate co-factor is required for activation of TRPA1 by irritant chemicals (Kim and Cavanaugh, 2007). Although this polyphosphate is required for activation of TRPA1 by pungent compounds, it is not required for cannabinoid activation of TRPA1 (Cavanaugh et al., 2008). These data suggest that ion channel or GPCR activity that affects intracellular IP3 concentrations will modulate the activation state and effective agonists of TRPA1. TRPA1 is also activated by elevation of intracellular calcium (Doerner et al., 2007) This effect is not dependent on polyphosphates or another soluble cysolic factor and is, therefore, functionally distinct from activation by pungent compounds or cannabinoids (Cavanaugh et al., 2008). It seems likely that pathways which result in elevation of intracellular calcium will enhance TRPA1 function; this calcium-driven modulation may allow TRPA1 to function as a coincidence detector of multiple stimuli in sensory neurons. Although less-studied than TRPV1, initial studies suggest that TRPA1 channel activity is modulated by PKA, PKC, PIP2 and IP3 in sensory neurons. TRPA1 is sensitized by both bradykinin and PAR2, suggesting a role for this channel in inflammatory pain. Furthermore, a recent study has shown immunohistochemical and functional upregulation of TRPA1 following the SNL model of nerve injury and increased behavioral responses to TRPA1 ligands in vivo (Ji et al., 2008). These data suggest that TRPA1 expression and ion channel modulation play an important role in both inflammatory and nerve injury-induced chronic pain. 7. Sensitization of TRPV1 by kinases is modulated by scaffold proteins Signaling mechanisms throughout the body are tightly coordinated and regulated by dynamic processes that control virtually every physiological system. The targeting, association, and orientation of signaling molecules in a transduction pathway are considered the points of highest control along the route of the original signal. Proteins including Membrane-Associated Guanylate Kinase homologs (MAGUK proteins; Willott et al., 1993; Woods and Bryant, 1991) and Ran Binding Protein in the Microtubule-Organizing Center (RanBPM; Yokoyama et al., 1995) serve as scaffolding proteins that organize multi-protein complexes. Scaffolding proteins serve to mediate and propagate signaling events, thereby reducing temporal, structural, and functional obstacles that would hinder the efficient coupling and association of pathway partners. Indeed, post-translational events that regulate the sensitivity of plasma membrane receptor/channels have been demonstrated to depend upon the organizational nature of scaffolding proteins. Recent biochemical studies of TRP family channels have identified the plasma membrane-localized isoform of A-Kinase Anchoring Protein (AKAP) scaffolding proteins as a critical link for inflammatory mediator-induced sensitization of TRPV1. Here we discuss the modulatory effects of AKAP scaffolding proteins on TRPV1 activity and sensitization. 7.1. TRPV1 channel activity is tightly regulated by post-translational modification Like other members of the TRP superfamily, native TRPV1 likely consists of four subunits, with each containing 6 transmembrane domains (Clapham, 2003). TRPV1 is expressed within a major class of nociceptive neurons (Helliwell et al., 1998) and appears to be an important receptor for detecting noxious stimuli such as acidic pH (Tominaga et al., 1998), heat (>43 °C) (Caterina et al., 1997), and chemicals including capsaicin (Caterina et al., 1997) and anandamide (Zygmunt et al., 1999). Analysis of TRPV1-deficient mice confirmed the specificity and activation kinetics of various receptor-specific stimuli (Caterina et al., 2000). Due to the multimodal sensory stimuli that can activate the receptor, TRPV1 is a particularly useful model for studying the biochemical regulation of receptor-activated sensitization of peripheral nociceptors. Early work that characterized release of neuropeptides from rat spinal cord following intrathecal infusion of capsaicin suggested that activation of the TRPV1 receptor/channel was regulated, at least in part, by post-translational modification (Jhamandas et al., 1984). The activation state of TRPV1 has been consistently shown to depend on the degree of post-translational modification, primarily phosphorylation (Lee et al., 2005). For example, tachyphylaxis, the pharmacological desensitization that follows repeated application of capsaicin, highlights the key role of phosphorylation and dephosphorylation in regulation of TRPV1 channel activity. Specifically, dephosphorylation of TRPV1 results in decreased channel activity. A key study by Docherty and colleagues showed that the neuronal phosphatase calcineurin plays a major role in dephosphorylating TRPV1, and is fundamentally responsible for the use-dependent decreases in channel activity in the presence of extracellular Ca2+ (Docherty et al., 1996; Wu et al., 2005). Conversely, phosphorylation of TRPV1 increases its activity and at least four unique serine/threonine kinases are known to phosphorylate and sensitize TRPV1, including Protein Kinase A (PKA), Protein Kinase C (PKC), Ca2+/calmodulin-dependent kinase II (CaMK II), and cyclin-dependent kinase 5 (Cdk5) (Ahern and Premkumar, 2002; Crandall et al., 2002; Jung et al., 2004; Numazaki et al., 2002; Pareek et al., 2007; Vellani et al., 2001). For example, PKA phosphorylates TRPV1 at amino acid sites Ser116, Thr144, Thr370, Ser502, Ser774, and Ser820 (Mohapatra and Nau, 2003; Rathee et al., 2002), and PKA activity is positively correlated with increased channel activity (Bhave et al., 2002; Hu et al., 2002; Mohapatra and Nau, 2003; Rathee et al., 2002). Surprisingly however, TRPV1 lacks a known binding domain for PKA association, suggesting that PKA must act via a scaffolding protein accomplice in order to modulate TRPV1 activity. 7.2. A-Kinase Anchoring Proteins serve as scaffolding partners for kinases A-Kinase Anchoring Proteins (AKAPs) were initially characterized as mediators of PKA signaling events and phosphorylation cascades (Bregman et al., 1989; Carr et al., 1992). Since their initial designation, over 20 AKAP isoforms have been identified and characterized in species ranging from C. elegans to Homo sapiens for their specific roles and subcellular localization (for review see Colledge and Scott, 1999). Among the AKAP isoforms that have been characterized, AKAP79/150 is predominantly localized to the plasma membrane and postsynaptic densities of neurons within the CNS (Dell’Acqua et al., 1998). In humans, AKAP79 is homologous with AKAP150 in rodents, and for convenience, we will refer to this protein as AKAP150. At postsynaptic densities, AKAP150 is found to bind to the RII subunits (RIIα and RIIβ) of PKA with nanomolar affinity (Carr et al., 1992). Importantly, AKAP150 is also present in rodent DRG neurons where it is essential for TRPV1 modulation (Schnizler et al., 2008). Further work has identified various other proteins that can associate with AKAP proteins in several tissues. For instance, AKAP150 has binding affinity with protein phosphatase 2B (PP2B, calcineurin) in addition to PKA (Coghlan et al., 1995). Interestingly, AKAP150 could potentially regulate both the phosphorylation and dephosphorylation of various proximal substrates, effectively controlling phosphorylation-dependent activities of substrate proteins (Faux and Scott, 1996), and thereby channel activity. Following this line of reasoning, several labs hypothesized that AKAP79/150 could regulate PKA-dependent sensitization of TRPV1 in peripheral neurons, thereby controlling the activity of the receptor and the sensation of pain. These observations support the suggestion that AKAP may play a role in the dynamic regulation of TRPV1 via both decreases and increases in activity by anchoring two different proteins that differentially modulate TRPV1 channel function. 7.3. AKAP150 and TRPV1 physically and functionally interact The initial suggestion of a functional AKAP/TRPV1 association was made in 2002, when Rathee and colleagues reported that forskolin-potentiated heat-induced currents in cultured DRG neurons could be blocked by inhibiting AKAP/PKA association (Rathee et al., 2002). Indeed, the Ca2+-mediated potentiation of heat-currents in dissociated DRG neurons was inhibited when PKA coupling to AKAP was disrupted. (Distler et al., 2003). Despite this, Rathee and colleagues were unable to demonstrate any physical interaction between AKAP and TRPV1 (Rathee et al., 2002). Nevertheless, a physical interaction between AKAP150 and TRPV1 was subsequently demonstrated in co-immunoprecipitation assays using both sensory neurons and Chinese Hamster Ovary (CHO) cells that express AKAP150 and TRPV1. Interestingly, MAGUK proteins that have been shown to bridge AKAP/effector protein interactions including PSD95 and SAP97 (Colledge et al., 2000), failed to co-immunoprecipitate with AKAP150 or TRPV1 in trigeminal sensory neurons. These results indicate that AKAP150 physically associates with TRPV1, either directly, or via the assistance of an unknown bridging protein that may be selectively expressed in sensory neurons. Given the number of TRP channels that exhibit heat sensitivity, a more specific link between TRPV1 and AKAP was established with the selective TRPV1 agonist capsaicin. When 8-Br-cAMP was used to stimulate PKA phosphorylation, the 8-Br-cAMP-induced sensitization of capsaicin-evoked Ca2+ transients in CHO cells required co-expression of TRPV1 and full-length AKAP150 proteins. In contrast, co-expression of TRPV1 with an AKAP150 mutant missing the PKA-binding domain (AKAP150ΔPKA) prevented 8-Br-cAMP from sensitizing the capsaicin-evoked Ca2+ influx. Furthermore, the 8-Br-cAMP-stimulated phosphorylation of TRPV1 and sensitization of capsaicin-evoked current in dissociated trigeminal neurons was significantly impaired in neurons transfected with AKAP150-specific siRNA compared to mock- or scrambled siRNA-transfected neurons, despite the fact that similar levels of PKA kinase activities were found in all groups of transfected neurons. These findings demonstrated that AKP150 functionally regulates the CAP-mediated activation and PKA-mediated sensitization of TRPV1. Further evidence for a function link between AKAP150 and PKA-induced modulation of TRPV1 comes from studies employing the peptide St-HT31, which inhibits PKA binding to AKAP150 and therefore the proper positioning of this kinase (Vijayaraghavan et al., 1997). In dissociated trigeminal neurons, pre-treatment with the St-HT31 blocked 8-Br-cAMP-stimulated TRPV1 phosphorylation. Importantly, the peripheral injection of St-HT31 significantly attenuates PGE2-stimulated thermal hyperalgesia (Jeske et al., 2008), confirming that both PKA and TRPV1 underlie this behavioral change. 7.4. AKAP serves as a linchpin for inflammatory mediators As illustrated in Fig. 15
Biochemical characterizations of receptor-mediated signaling systems often fail to account for supporting proteins that play a significant role in modulating post-translational changes in the receptor complex. The AKAP150 scaffolding protein serves such a purpose as it allows for the close spatial association of PKA, and other potential signaling enzymes, with TRPV1 at the level of the plasma membrane in primary afferent neurons. Indeed, such an association supports an efficient pathway for inflammatory sensitization, thereby identifying the scaffolding protein as a potential therapeutic target for inflammatory hyperalgesia over the signaling enzymes themselves. The identification and subsequent characterization of peptide sequences responsible for TRPV1/AKAP150 association would provide a unique target for the generation of peripheral inflammatory analgesics, and could even be used to dissect the associations of other potential signaling enzymes that post-translationally modify TRPV1. 8. Closing remarks Knowledge about the function of TRPV1, TRPM8 and TRPA1 has rapidly developed since their discoveries within the past eleven years. A theme that emerges from this review is that TRPV1, TRPM8 and TRPA1 are not simple channel mediators of heat, cold and pungency, respectively, but instead serve multidimensional roles in signaling multimodal sensory stimuli. TRPM8 is required for cold detection, and contributes to cold pain, cold hypersensitivity after injury, and cooling analgesia. TRPV1 is a molecular fulcrum for activation and sensitization of primary afferent neurons to heat, acid, and numerous endogenous inflammatory mediators and is a plays an essential role in the peripheral hyperalgesia that accompanies tissue injury. Growing evidence indicates that TRPA1 acts as a similar molecular integrator, via its activation, sensitization and facilitation of multiple signaling pathways, including sensory transduction, nociception, inflammation and oxidative stress. Whereas significant strides for roles of these channels are being made at the cellular level in nociceptors, other levels of the nervous system that need to be charted include their roles in synaptic plasticity in the spinal cord, brainstem and descending systems. We anticipated that by the next Spring Pain meeting, the information about functional roles of TRPV1, TRPM8 and TRPA1 will have multiplied exponentially. Acknowledgments The authors wish to thank Yoshio Takashima and the members of the McKemy lab for their support and insights related to this work. Furthermore, the authors wish to thank Joshua Glazer and Diana Bautista for their contributions. Thanks to Ardem Patapoutian, Bialong Xiao, Lindsey Macpherson, Matt Petrus, Andrea Peier, Michael Bandell, Sun Wook Hwang, Truc Huynh, Nicholas Olney and Tim Jegla. This research was supported by grants NS40538 (C.L.S), NS054069 (D.D.M), NS061884 (N.A.J), NS31826 and NS050758 (to B.M. Davis for S.A.M) and NIDDK 063922 (S.A.M). References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||||||||||||
Nat Chem Biol. 2005 Jul; 1(2):85-92.
[Nat Chem Biol. 2005]Sci STKE. 2005 Feb 22; 2005(272):re3.
[Sci STKE. 2005]Nature. 1997 Oct 23; 389(6653):816-24.
[Nature. 1997]Neuron. 1998 Sep; 21(3):531-43.
[Neuron. 1998]Nature. 2002 Mar 7; 416(6876):52-8.
[Nature. 2002]Cell. 2002 Mar 8; 108(5):705-15.
[Cell. 2002]Nature. 2007 Jul 12; 448(7150):204-8.
[Nature. 2007]Neuron. 2007 May 3; 54(3):371-8.
[Neuron. 2007]Neuron. 2007 May 3; 54(3):379-86.
[Neuron. 2007]J Biol Chem. 1999 Mar 12; 274(11):7325-33.
[J Biol Chem. 1999]Cell. 2003 Mar 21; 112(6):819-29.
[Cell. 2003]Nature. 2003 Dec 4; 426(6966):517-24.
[Nature. 2003]Neuron. 2004 Mar 25; 41(6):849-57.
[Neuron. 2004]Nature. 2004 Jan 15; 427(6971):260-5.
[Nature. 2004]Nature. 2002 Mar 7; 416(6876):52-8.
[Nature. 2002]Cell. 2002 Mar 8; 108(5):705-15.
[Cell. 2002]Nature. 2007 Jul 12; 448(7150):204-8.
[Nature. 2007]Neuron. 2007 May 3; 54(3):379-86.
[Neuron. 2007]Neuron. 2007 May 3; 54(3):371-8.
[Neuron. 2007]J Physiol. 1991 Apr; 435():41-63.
[J Physiol. 1991]Nature. 2007 Jul 12; 448(7150):204-8.
[Nature. 2007]Nature. 2002 Mar 7; 416(6876):52-8.
[Nature. 2002]Nat Neurosci. 2002 Mar; 5(3):254-60.
[Nat Neurosci. 2002]J Neurosci. 2007 Mar 7; 27(10):2435-43.
[J Neurosci. 2007]J Neurophysiol. 1973 Mar; 36(2):325-46.
[J Neurophysiol. 1973]J Physiol. 1987 Oct; 391():193-207.
[J Physiol. 1987]Pain. 1998 Mar; 75(1):47-57.
[Pain. 1998]Pain. 1998 Mar; 75(1):47-57.
[Pain. 1998]Pain. 1999 Nov; 83(2):123-35.
[Pain. 1999]Nature. 2007 Jul 12; 448(7150):204-8.
[Nature. 2007]Neuron. 2007 May 3; 54(3):379-86.
[Neuron. 2007]Neuron. 2007 May 3; 54(3):371-8.
[Neuron. 2007]Nature. 2007 Jul 12; 448(7150):204-8.
[Nature. 2007]Neuron. 2007 May 3; 54(3):379-86.
[Neuron. 2007]Neuron. 2007 May 3; 54(3):371-8.
[Neuron. 2007]Cell. 2003 Mar 21; 112(6):819-29.
[Cell. 2003]Neuron. 2004 Mar 25; 41(6):849-57.
[Neuron. 2004]Brain Res. 2007 Jul 30; 1160():39-46.
[Brain Res. 2007]Cell. 2006 Mar 24; 124(6):1269-82.
[Cell. 2006]Nature. 2004 Jan 15; 427(6971):260-5.
[Nature. 2004]Cell. 2003 Apr 18; 113(2):261-73.
[Cell. 2003]Nat Neurosci. 2007 May; 10(5):568-77.
[Nat Neurosci. 2007]Neuron. 2006 Apr 20; 50(2):277-89.
[Neuron. 2006]Cell. 2006 Mar 24; 124(6):1269-82.
[Cell. 2006]Mol Pain. 2007 Dec 17; 3():40.
[Mol Pain. 2007]J Neurosci. 2008 Mar 5; 28(10):2485-94.
[J Neurosci. 2008]Neuron. 2004 Mar 25; 41(6):849-57.
[Neuron. 2004]Mol Pain. 2008 Jul 31; 4():30.
[Mol Pain. 2008]J Pharmacol Exp Ther. 2005 Dec; 315(3):1136-42.
[J Pharmacol Exp Ther. 2005]Neuroscience. 1996 Oct; 74(4):1111-23.
[Neuroscience. 1996]J Neurosci. 2002 Sep 1; 22(17):7444-52.
[J Neurosci. 2002]Vitam Horm. 2000; 58():89-120.
[Vitam Horm. 2000]Nat Med. 1999 Jun; 5(6):698-701.
[Nat Med. 1999]Ann N Y Acad Sci. 1996 Dec 27; 804():266-75.
[Ann N Y Acad Sci. 1996]Biochem Biophys Res Commun. 2005 Nov 18; 337(2):521-5.
[Biochem Biophys Res Commun. 2005]Proc Natl Acad Sci U S A. 2000 Apr 25; 97(9):4844-9.
[Proc Natl Acad Sci U S A. 2000]Nature. 1998 Jan 1; 391(6662):82-6.
[Nature. 1998]Proc Natl Acad Sci U S A. 2006 Dec 19; 103(51):19564-8.
[Proc Natl Acad Sci U S A. 2006]Nature. 2007 Feb 1; 445(7127):541-5.
[Nature. 2007]Mol Pharmacol. 2008 Feb; 73(2):274-81.
[Mol Pharmacol. 2008]J Neurosci. 2008 Mar 5; 28(10):2485-94.
[J Neurosci. 2008]Mol Pain. 2008 Jul 31; 4():30.
[Mol Pain. 2008]Cell. 2003 Mar 21; 112(6):819-29.
[Cell. 2003]Neuron. 2004 Mar 25; 41(6):849-57.
[Neuron. 2004]Cell. 2006 Mar 24; 124(6):1269-82.
[Cell. 2006]Neuron. 2004 Mar 25; 41(6):849-57.
[Neuron. 2004]Cell. 2006 Mar 24; 124(6):1269-82.
[Cell. 2006]Proc Natl Acad Sci U S A. 2006 Dec 19; 103(51):19564-8.
[Proc Natl Acad Sci U S A. 2006]Curr Biol. 2005 May 24; 15(10):929-34.
[Curr Biol. 2005]Proc Natl Acad Sci U S A. 2007 Aug 14; 104(33):13525-30.
[Proc Natl Acad Sci U S A. 2007]J Pharmacol Exp Ther. 2008 Jan; 324(1):313-21.
[J Pharmacol Exp Ther. 2008]J Immunol. 2008 Jan 1; 180(1):609-17.
[J Immunol. 2008]Nature. 2007 Feb 1; 445(7127):541-5.
[Nature. 2007]Proc Natl Acad Sci U S A. 2006 Dec 19; 103(51):19564-8.
[Proc Natl Acad Sci U S A. 2006]J Neurosci. 2007 Oct 17; 27(42):11412-5.
[J Neurosci. 2007]Nature. 2007 Feb 1; 445(7127):541-5.
[Nature. 2007]Prog Lipid Res. 2003 Jul; 42(4):318-43.
[Prog Lipid Res. 2003]Proc Natl Acad Sci U S A. 2007 Aug 14; 104(33):13525-30.
[Proc Natl Acad Sci U S A. 2007]Proc Natl Acad Sci U S A. 2007 Aug 14; 104(33):13519-24.
[Proc Natl Acad Sci U S A. 2007]Pain. 1992 Oct; 51(1):5-17.
[Pain. 1992]J Neurosci. 2007 Oct 17; 27(42):11412-5.
[J Neurosci. 2007]Proc Natl Acad Sci U S A. 2007 Aug 14; 104(33):13525-30.
[Proc Natl Acad Sci U S A. 2007]Mol Pain. 2007 Dec 17; 3():40.
[Mol Pain. 2007]Neuron. 2006 Apr 20; 50(2):277-89.
[Neuron. 2006]Nat Neurosci. 2007 Mar; 10(3):277-9.
[Nat Neurosci. 2007]Neuron. 2006 Apr 20; 50(2):277-89.
[Neuron. 2006]Cell. 2006 Mar 24; 124(6):1269-82.
[Cell. 2006]J Clin Invest. 2005 Sep; 115(9):2393-401.
[J Clin Invest. 2005]Mol Pain. 2005 Dec 14; 1():36.
[Mol Pain. 2005]Science. 2000 Apr 14; 288(5464):306-13.
[Science. 2000]J Neurosci. 2005 Mar 23; 25(12):3126-31.
[J Neurosci. 2005]Pain. 2005 Jun; 115(3):296-307.
[Pain. 2005]J Urol. 2007 Apr; 177(4):1537-41.
[J Urol. 2007]Gastroenterology. 2007 Jul; 133(1):184-94.
[Gastroenterology. 2007]J Neurosci. 2006 Aug 16; 26(33):8588-99.
[J Neurosci. 2006]Pain. 2005 Sep; 117(1-2):68-76.
[Pain. 2005]Anesthesiology. 2007 Jul; 107(1):128-35.
[Anesthesiology. 2007]Neurosci Lett. 1999 Oct 29; 274(3):159-62.
[Neurosci Lett. 1999]J Neurophysiol. 2004 Nov; 92(5):3148-52.
[J Neurophysiol. 2004]Proc Natl Acad Sci U S A. 2005 Aug 23; 102(34):12248-52.
[Proc Natl Acad Sci U S A. 2005]J Comp Neurol. 2005 Dec 26; 493(4):596-606.
[J Comp Neurol. 2005]Science. 2000 Apr 14; 288(5464):306-13.
[Science. 2000]Br J Pharmacol. 2004 Mar; 141(5):787-94.
[Br J Pharmacol. 2004]Cell. 2006 Mar 24; 124(6):1269-82.
[Cell. 2006]Pflugers Arch. 1996 Apr; 431(6):828-37.
[Pflugers Arch. 1996]J Biol Chem. 2005 Apr 8; 280(14):13424-32.
[J Biol Chem. 2005]Nature. 2001 Jun 21; 411(6840):957-62.
[Nature. 2001]J Neurosci. 2005 May 11; 25(19):4835-43.
[J Neurosci. 2005]J Physiol. 2007 Aug 15; 583(Pt 1):175-93.
[J Physiol. 2007]Brain. 2008 May; 131(Pt 5):1241-51.
[Brain. 2008]Neuron. 2004 Mar 25; 41(6):849-57.
[Neuron. 2004]Cell. 2006 Mar 24; 124(6):1269-82.
[Cell. 2006]Neuron. 2006 Apr 20; 50(2):277-89.
[Neuron. 2006]J Neurosci. 2007 Jun 13; 27(24):6500-9.
[J Neurosci. 2007]Neuroscience. 2008 Jul 17; 154(4):1467-76.
[Neuroscience. 2008]J Biol Chem. 2007 May 4; 282(18):13180-9.
[J Biol Chem. 2007]Neuroscience. 2008 Jun 26; 154(3):1054-66.
[Neuroscience. 2008]Proc Natl Acad Sci U S A. 1993 Aug 15; 90(16):7834-8.
[Proc Natl Acad Sci U S A. 1993]Cell. 1991 Aug 9; 66(3):451-64.
[Cell. 1991]Nature. 1995 Jul 13; 376(6536):184-8.
[Nature. 1995]Nature. 2003 Dec 4; 426(6966):517-24.
[Nature. 2003]Neurosci Lett. 1998 Jul 10; 250(3):177-80.
[Neurosci Lett. 1998]Neuron. 1998 Sep; 21(3):531-43.
[Neuron. 1998]Nature. 1997 Oct 23; 389(6653):816-24.
[Nature. 1997]Nature. 1999 Jul 29; 400(6743):452-7.
[Nature. 1999]Brain Res. 1984 Jul 23; 306(1-2):215-25.
[Brain Res. 1984]Arch Pharm Res. 2005 Apr; 28(4):405-12.
[Arch Pharm Res. 2005]Pflugers Arch. 1996 Apr; 431(6):828-37.
[Pflugers Arch. 1996]J Biol Chem. 2005 May 6; 280(18):18142-51.
[J Biol Chem. 2005]J Physiol. 2002 Dec 1; 545(Pt 2):441-51.
[J Physiol. 2002]J Biol Chem. 1989 Mar 15; 264(8):4648-56.
[J Biol Chem. 1989]J Biol Chem. 1992 Aug 25; 267(24):16816-23.
[J Biol Chem. 1992]Trends Cell Biol. 1999 Jun; 9(6):216-21.
[Trends Cell Biol. 1999]EMBO J. 1998 Apr 15; 17(8):2246-60.
[EMBO J. 1998]Science. 1995 Jan 6; 267(5194):108-11.
[Science. 1995]Cell. 1996 Apr 5; 85(1):9-12.
[Cell. 1996]J Neurosci. 2002 Jun 1; 22(11):4740-5.
[J Neurosci. 2002]J Neurophysiol. 2003 May; 89(5):2499-505.
[J Neurophysiol. 2003]Neuron. 2000 Jul; 27(1):107-19.
[Neuron. 2000]J Biol Chem. 1997 Feb 21; 272(8):4747-52.
[J Biol Chem. 1997]Pain. 2008 Sep 15; 138(3):604-16.
[Pain. 2008]J Neurosci. 2002 Sep 1; 22(17):7444-52.
[J Neurosci. 2002]J Physiol. 2006 Nov 1; 576(Pt 3):809-22.
[J Physiol. 2006]Neurosci Lett. 2004 May 6; 361(1-3):159-62.
[Neurosci Lett. 2004]J Neurophysiol. 1996 Sep; 76(3):1396-404.
[J Neurophysiol. 1996]J Neurosci. 2007 Dec 19; 27(51):14147-57.
[J Neurosci. 2007]Nature. 2007 Jul 12; 448(7150):204-8.
[Nature. 2007]